NEXTBio Capital Management LP Takes Position in Oculis Holding AG $OCS

NEXTBio Capital Management LP bought a new stake in Oculis Holding AG (NASDAQ:OCS) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 149,750 shares of the company’s stock, valued at approximately $2,991,000. Oculis accounts for 1.8% of NEXTBio Capital Management LP’s investment portfolio, making the stock its 20th biggest holding. NEXTBio Capital Management LP owned approximately 0.29% of Oculis as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Gildi lifeyrissjodur acquired a new stake in shares of Oculis in the fourth quarter valued at about $50,250,000. Aberdeen Group plc lifted its stake in shares of Oculis by 39.4% in the fourth quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock worth $34,887,000 after buying an additional 493,827 shares in the last quarter. SR One Capital Management LP lifted its stake in shares of Oculis by 98.8% in the fourth quarter. SR One Capital Management LP now owns 641,022 shares of the company’s stock worth $12,801,000 after buying an additional 318,522 shares in the last quarter. Alyeska Investment Group L.P. lifted its stake in shares of Oculis by 152.3% in the fourth quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock worth $6,617,000 after buying an additional 200,000 shares in the last quarter. Finally, Syquant Capital Sas purchased a new position in shares of Oculis in the fourth quarter worth about $3,849,000. Institutional investors and hedge funds own 22.30% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on OCS. JPMorgan Chase & Co. decreased their price target on shares of Oculis from $42.00 to $23.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 3rd. Robert W. Baird decreased their price target on shares of Oculis from $49.00 to $38.00 and set an “outperform” rating on the stock in a research note on Monday, June 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a research note on Tuesday, April 21st. Needham & Company LLC decreased their price target on shares of Oculis from $46.00 to $38.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. Finally, Stifel Nicolaus decreased their price target on shares of Oculis from $50.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $38.33.

Oculis Price Performance

Shares of OCS opened at $11.09 on Friday. Oculis Holding AG has a 1-year low of $10.52 and a 1-year high of $34.47. The stock has a market cap of $643.00 million, a PE ratio of -5.21 and a beta of 0.23. The firm has a 50-day simple moving average of $24.99 and a two-hundred day simple moving average of $24.65. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.18 and a quick ratio of 5.18.

Oculis (NASDAQ:OCS) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. The company had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.25 million. As a group, analysts forecast that Oculis Holding AG will post -2.27 EPS for the current year.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.